Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.
Cancer immunotherapy
Immuno-imaging
Positron emission tomography
Response evaluation
Tumor-reactive T-cells
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
13
08
2021
accepted:
05
01
2022
entrez:
31
1
2022
pubmed:
1
2
2022
medline:
1
2
2022
Statut:
epublish
Résumé
In the last decades, our understanding of the role of the immune system in cancer has significantly improved and led to the discovery of new immunotherapeutic targets and tools, which boosted the advances in cancer immunotherapy to fight a growing number of malignancies. Approved immunotherapeutic approaches are currently mainly based on immune checkpoint inhibitors, antibody-derived targeted therapies, or cell-based immunotherapies. In essence, these therapies induce or enhance the infiltration and function of tumor-reactive T cells within the tumors, ideally resulting in complete tumor eradication. While the clinical application of immunotherapies has shown great promise, these therapies are often accompanied either by a variety of side effects as well as partial or complete unresponsiveness of a number of patients. Since different stages of disease progression elicit different local and systemic immune responses, the ability to longitudinally interrogate the migration and expansion of immune cells, especially T cells, throughout the whole body might greatly facilitate disease characterization and understanding. Furthermore, it can serve as a tool to guide development as well as selection of appropriate treatment regiments. This review provides an overview about a variety of immune-imaging tools available to characterize and study T-cell responses induced by anti-cancer immunotherapy. Moreover, challenges are discussed that must be taken into account and overcome to use immune-imaging tools as predictive and surrogate markers to enhance assessment and successful application of immunotherapies.
Identifiants
pubmed: 35099641
doi: 10.1186/s13550-022-00877-z
pii: 10.1186/s13550-022-00877-z
pmc: PMC8804060
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB824 / C10
Organisme : Deutsche Forschungsgemeinschaft
ID : TRR338
Informations de copyright
© 2022. The Author(s).
Références
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
EJNMMI Res. 2013 May 08;3(1):36
pubmed: 23651690
Nature. 1987 Mar 26-Apr 1;326(6111):400-3
pubmed: 2951597
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):286-295
pubmed: 27573793
J Nucl Med. 2020 Sep;61(9):1355-1360
pubmed: 32111688
Theranostics. 2018 Nov 28;8(21):6070-6087
pubmed: 30613283
Front Physiol. 2020 Apr 03;11:154
pubmed: 32327996
Bioconjug Chem. 2009 Dec;20(12):2254-61
pubmed: 19921791
Anal Bioanal Chem. 2019 Mar;411(9):1703-1713
pubmed: 30734854
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Cancer Res. 2017 May 1;77(9):2318-2327
pubmed: 28461564
Curr Hematol Malig Rep. 2019 Aug;14(4):286-291
pubmed: 31187421
Cancer. 2008 Sep 15;113(6):1387-95
pubmed: 18671239
Cancer Res. 2016 Jan 1;76(1):73-82
pubmed: 26573799
Semin Nucl Med. 2010 May;40(3):167-81
pubmed: 20350626
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
J Exp Med. 2017 Aug 7;214(8):2243-2255
pubmed: 28666979
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Chem Rev. 2020 Apr 22;120(8):3787-3851
pubmed: 32202104
Mol Ther. 2019 Jan 2;27(1):219-229
pubmed: 30429045
Oncotarget. 2018 Jul 13;9(54):30268-30278
pubmed: 30100988
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
ChemMedChem. 2018 Dec 6;13(23):2466-2478
pubmed: 30246488
Contrast Media Mol Imaging. 2018 Oct 25;2018:5603902
pubmed: 30498401
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Int J Cancer. 1990 Dec 15;46(6):1035-40
pubmed: 1979068
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4369-4376
pubmed: 34076745
Chem Biol. 2005 May;12(5):567-77
pubmed: 15911377
Blood Adv. 2020 Apr 14;4(7):1367-1377
pubmed: 32267932
Immunity. 2004 Oct;21(4):503-13
pubmed: 15485628
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
J Nucl Med. 2021 Aug 19;:
pubmed: 34413145
Sci Transl Med. 2017 Nov 22;9(417):
pubmed: 29167392
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
Cancer Immunol Res. 2019 Jan;7(1):150-161
pubmed: 30459153
J Mol Biol. 2010 Apr 30;398(2):232-47
pubmed: 20226194
J Clin Oncol. 1989 Feb;7(2):250-61
pubmed: 2644399
Nature. 2019 Sep;573(7775):546-552
pubmed: 31461748
PLoS One. 2018 Mar 7;13(3):e0193832
pubmed: 29513764
J Immunol. 2016 Nov 1;197(9):3431-3436
pubmed: 27824589
Oncogene. 2021 Feb;40(8):1393-1395
pubmed: 33500548
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Cancer Res. 2016 Jul 15;76(14):4113-23
pubmed: 27354381
Oncoimmunology. 2016 Nov 18;6(1):e1248014
pubmed: 28197364
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Nucl Med. 2021 Nov;62(11):1638-1644
pubmed: 33712537
Angew Chem Int Ed Engl. 2008;47(26):4922-5
pubmed: 18496798
Cancer Res. 2006 Sep 1;66(17):8878-86
pubmed: 16951205
Mol Cell Biol. 1987 Feb;7(2):650-6
pubmed: 2434833
Lancet Oncol. 2017 Oct;18(10):1302
pubmed: 28919084
Immunol Res. 2001;24(1):31-52
pubmed: 11485208
Bioconjug Chem. 2015 Oct 21;26(10):2062-9
pubmed: 26307602
J Immunol. 2001 Feb 15;166(4):2394-403
pubmed: 11160298
J Nanobiotechnology. 2021 Feb 9;19(1):42
pubmed: 33563286
PLoS One. 2014 Nov 03;9(11):e109866
pubmed: 25365349
J Nucl Med. 2017 Nov;58(11):1852-1857
pubmed: 28588151
J Immunol. 2011 Oct 15;187(8):4100-8
pubmed: 21930972
ChemMedChem. 2020 Feb 5;15(3):284-292
pubmed: 31830368
Gut. 1997 Jan;40(1):113-9
pubmed: 9155587
J Labelled Comp Radiopharm. 2018 Jul;61(9):652-671
pubmed: 29230857
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Mol Ther. 2020 Jun 3;28(6):1392-1416
pubmed: 32243834
Am J Gastroenterol. 2005 Feb;100(2):344-54
pubmed: 15667492
Radiother Oncol. 1999 Feb;50(2):199-204
pubmed: 10368044
Mol Imaging Biol. 2010 Oct;12(5):539-46
pubmed: 19949980
Transplantation. 1992 Nov;54(5):844-51
pubmed: 1440852
J Nucl Med. 2014 May;55(5):730-5
pubmed: 24665085
Clin Cancer Res. 2020 Jan 15;26(2):332-339
pubmed: 31413009
EBioMedicine. 2021 Jan;63:103137
pubmed: 33310681
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
J Immunol Methods. 2013 Jul 31;393(1-2):38-44
pubmed: 23597928
Radiat Res. 2004 Jul;162(1):1-19
pubmed: 15222781
Nucl Med Commun. 2008 Mar;29(3):193-207
pubmed: 18349789
Biomolecules. 2019 Sep 29;9(10):
pubmed: 31569553
Mol Imaging Biol. 2017 Aug;19(4):599-609
pubmed: 27966069
J Nucl Med. 2020 Apr;61(4):512-519
pubmed: 31586002
J Immunother Cancer. 2021 Sep;9(9):
pubmed: 34518289
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Clin Cancer Res. 2018 Oct 15;24(20):4976-4987
pubmed: 29967252
Chem Soc Rev. 2014 Jan 7;43(1):260-90
pubmed: 24173525
Theranostics. 2019 Oct 16;9(25):7924-7947
pubmed: 31656546
Mol Imaging Biol. 2011 Jun;13(3):526-535
pubmed: 20628903
Theranostics. 2017 Jul 14;7(11):2924-2939
pubmed: 28824726
Methods. 2014 Jan 1;65(1):139-47
pubmed: 24091005
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1161-6
pubmed: 25587131
Clin Transl Imaging. 2018;6(2):145-148
pubmed: 29670866
Biomark Res. 2018 Jan 22;6:4
pubmed: 29387417
Nature. 1984 Dec 6-12;312(5994):548-51
pubmed: 6150440
Clin Cancer Res. 2019 Dec 1;25(23):7014-7023
pubmed: 31540979
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1128-35
pubmed: 21093169
Theranostics. 2017 Jun 15;7(9):2402-2416
pubmed: 28744323
J Nucl Med. 2004 Oct;45(10):1647-52
pubmed: 15471828
Clin Cancer Res. 2019 Feb 15;25(4):1196-1205
pubmed: 30327313
J Nucl Med. 2016 Oct;57(10):1607-1611
pubmed: 27230929
Expert Opin Drug Deliv. 2014 Dec;11(12):1939-54
pubmed: 25035968
Cancers (Basel). 2020 Mar 11;12(3):
pubmed: 32168760
Sci Immunol. 2019 Jan 11;4(31):
pubmed: 30635355
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Transplantation. 2002 Nov 27;74(10):1454-60
pubmed: 12451248
Eur J Haematol. 1989 Mar;42(3):276-83
pubmed: 2494057
J Nucl Med. 2018 Dec;59(12):1892-1893
pubmed: 30442751
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):694-707
pubmed: 32889615
Cancer Immunol Res. 2020 Mar;8(3):334-344
pubmed: 31871122
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Cancer. 1996 Apr 1;77(7):1303-10
pubmed: 8608507
Front Immunol. 2020 Jun 02;11:1067
pubmed: 32582173